ADMA Biologics, Inc.

NasdaqGM:ADMA Stok Raporu

Piyasa değeri: US$5.1b

ADMA Biologics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

ADMA Biologics yıllık ortalama 29.4% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 19.1% annual. Gelirler growing yılda ortalama 49.4% oranında artmaktadır. ADMA Biologics'in özkaynak karlılığı 29.4% ve net marjı 17.8%'dir.

Anahtar bilgiler

29.4%

Kazanç büyüme oranı

47.8%

EPS büyüme oranı

Biotechs Sektör Büyümesi17.0%
Gelir büyüme oranı49.4%
Özkaynak getirisi29.4%
Net Marj17.8%
Son Kazanç Güncellemesi30 Sep 2024

Yakın geçmiş performans güncellemeleri

ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality

Aug 16
ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality

Recent updates

ADMA Biologics, Inc.'s (NASDAQ:ADMA) 27% Price Boost Is Out Of Tune With Revenues

Oct 09
ADMA Biologics, Inc.'s (NASDAQ:ADMA) 27% Price Boost Is Out Of Tune With Revenues

ADMA Biologics: Riding High On ASCENIV's Success

Oct 02

ADMA Biologics, Inc.'s (NASDAQ:ADMA) Intrinsic Value Is Potentially 57% Above Its Share Price

Sep 06
ADMA Biologics, Inc.'s (NASDAQ:ADMA) Intrinsic Value Is Potentially 57% Above Its Share Price

ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality

Aug 16
ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality

ADMA Biologics: A Compelling GARP Stock For Biotech Investors

Jul 27

ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Jul 24
ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?

Jul 17
Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?

Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?

May 30
Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?

ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next

May 13
ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next

Giving ADMA Biologics A Well-Deserved 'Booyah'

May 12

ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares

May 08
ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares

Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?

Apr 04
Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?

Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)

Apr 03

ADMA Biologics: On A Roll Entering 2024

Jan 19

Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?

Jan 09
Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?

ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Jan 09
ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement

We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

Oct 25
We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

Jun 10
We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet

May 12
The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet

ADMA Biologics: Strong Growth Is Clearing The Path To Profitability

Aug 21

ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M

Aug 10

ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt

Jun 01
ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt

ADMA Biologics: A Path To Profits Looks Clear

May 12

ADMA: Pertinent Updates

Apr 18

ADMA Biologics' 2021 Numbers Showed Continued Strong Execution

Mar 29

Gelir ve Gider Dağılımı

ADMA Biologics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqGM:ADMA Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Sep 2438368692
30 Jun 2433035652
31 Mar 24283-4633
31 Dec 23258-28633
30 Sep 23234-23664
30 Jun 23208-40694
31 Mar 23182-48694
31 Dec 22154-66704
30 Sep 22130-70682
30 Jun 22110-73642
31 Mar 2294-78612
31 Dec 2181-72553
30 Sep 2169-74494
30 Jun 2158-74465
31 Mar 2148-75435
31 Dec 2042-76396
30 Sep 2040-67365
30 Jun 2037-61334
31 Mar 2036-54303
31 Dec 1929-48282
30 Sep 1921-56293
30 Jun 1918-59293
31 Mar 1916-61294
31 Dec 1817-66304
30 Sep 1818-61304
30 Jun 1818-61285
31 Mar 1817-55235
31 Dec 1716-44216
30 Sep 1714-35185
30 Jun 1712-24165
31 Mar 1711-21177
31 Dec 1611-20148
30 Sep 1610-20129
30 Jun 169-201210
31 Mar 168-19128
31 Dec 157-18117
30 Sep 156-17117
30 Jun 156-1596
31 Mar 156-1597
31 Dec 146-17910
30 Sep 145-18811
30 Jun 145-17810
31 Mar 144-18712
31 Dec 133-1679

Kaliteli Kazançlar: ADMA büyük bir tek seferlik zarar ile $29.0M, 30th September, 2024 tarihine ait son 12 aylık mali sonuçları etkiliyor.

Büyüyen Kar Marjı: ADMA geçmişte karlı hale geldi.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: ADMA son 5 yılda karlı hale geldi ve kazançlarını yıllık 29.4% oranında artırdı.

Büyüme Hızlandırma: ADMA son bir yılda karlı hale geldi, bu da kazanç büyüme oranının 5 yıllık ortalamayla karşılaştırılmasını zorlaştırıyor.

Kazançlar vs. Sektör: ADMA son bir yılda karlı hale geldi ve bu durum, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 16.6% ) karşılaştırılmasını zorlaştırıyor.


Özkaynak Getirisi

Yüksek ROE: ADMA 'nin Özsermaye Getirisi ( 29.4% ) yüksek olarak değerlendiriliyor.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin